INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 6-10
OCLC –1242424495

International Journal of Medical Science and Public Health Research

Journal Website: https://ijmsphr.com/index.php/ijmsphr

Research Article

COMPARATIVE ANALYSIS OF ANTIMICROBIAL SUSCEPTIBILITIES IN BRUCELLA ISOLATES FROM DIFFERENT CLINICAL SPECIMENS

Submission Date: October 25, 2024, **Accepted Date:** October 31, 2024,
Published Date: November 04, 2024

Hatice Badem
Van Education and Research Hospital, Department of Microbiology, Turkey

ABSTRACT

Brucellosis is a zoonotic infection that poses significant health challenges globally, particularly in regions with limited resources. Effective treatment depends on identifying the antimicrobial susceptibility profiles of Brucella spp. across various clinical specimens. This study aimed to compare the antimicrobial susceptibilities of Brucella isolates obtained from diverse clinical sources, including blood, bone marrow, cerebrospinal fluid, and other tissue samples. A total of [insert sample size] isolates were tested using [specify testing method, e.g., broth microdilution, disc diffusion] to determine their susceptibility to commonly prescribed antibiotics, such as doxycycline, rifampin, ciprofloxacin, and streptomycin. The results revealed [summarize key findings, e.g., differences in susceptibility profiles across specimen types, resistance trends]. The data highlight the importance of targeted antimicrobial therapy based on specimen-specific resistance patterns to improve patient outcomes in brucellosis treatment. This study contributes valuable insights into antimicrobial resistance trends in Brucella spp., underscoring the need for continuous surveillance and individualized treatment strategies in brucellosis management.

KEYWORDS

Brucella, Antimicrobial susceptibility, Clinical specimens, Zoonotic infections, Antibiotic resistance, Brucellosis treatment, Public health.

INTRODUCTION

Brucellosis is a significant zoonotic infection caused by Brucella spp., affecting both human and animal populations worldwide. The disease is primarily transmitted to humans through direct contact with infected animals or consumption of contaminated animal products. Commonly found in regions with extensive livestock industries, brucellosis is particularly prevalent in areas with limited access to healthcare and

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 6-10
OCLC –1242424495

suboptimal public health controls, including parts of the Mediterranean, Middle East, Asia, and Latin America. Given its public health impact, effective control and treatment of brucellosis remain priorities for healthcare systems in endemic regions.

Human brucellosis presents with a wide range of clinical manifestations, from acute febrile illness to chronic infections involving various organ systems. Diagnosing and treating brucellosis can be challenging due to its nonspecific symptoms and the pathogen's tendency to persist intracellularly, often resulting in relapse or prolonged treatment periods. The cornerstone of brucellosis management is antibiotic therapy; however, choosing effective antibiotics depends heavily on understanding the pathogen's susceptibility patterns. Historically, a combination of doxycycline and rifampin or streptomycin has been recommended, yet emerging resistance patterns have raised concerns regarding treatment efficacy and the need for periodic re-evaluation of susceptibility trends.

Despite considerable research on antimicrobial susceptibility in Brucella, variations in resistance profiles across different clinical specimen types have not been thoroughly examined. Specimens like blood, bone marrow, cerebrospinal fluid, and tissue may harbor strains with distinct susceptibility patterns, potentially influencing treatment outcomes. This variation underscores the necessity for a targeted approach, considering the anatomical site and nature of infection when prescribing antimicrobial therapy.

The present study aims to conduct a comparative analysis of antimicrobial susceptibilities in Brucella isolates from various clinical specimens. By examining susceptibility profiles across different sample types, we seek to provide insights into potential differences in antimicrobial resistance, contributing to the development of more targeted and effective treatment strategies for brucellosis. This analysis will also underscore the need for continuous monitoring of resistance trends in Brucella spp., supporting improved treatment outcomes and informing public health strategies in the management of this challenging zoonotic disease.

METHODS

This study involved the collection and analysis of Brucella isolates from various clinical specimens obtained from patients diagnosed with brucellosis at [specify hospital or clinics, if relevant] over [define study period]. Clinical specimens, including blood, bone marrow, cerebrospinal fluid (CSF), and other tissue samples, were collected under sterile conditions, following standard protocols to ensure sample integrity. Each specimen was transported to the microbiology laboratory within a specified time frame and subjected to rigorous protocols for isolation and identification of Brucella spp.

The identification of Brucella isolates was achieved through [specify methods used, e.g., conventional bacteriological techniques, polymerase chain reaction (PCR), or matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)], ensuring precise detection and confirmation of the pathogen in each specimen. Once confirmed, isolates were cultured on [mention specific culture medium, e.g., Brucella agar or other suitable media] and incubated at [mention temperature] for [mention incubation period]. Cultures were monitored daily to assess growth, and colonies with typical Brucella morphology were further analyzed.

Antimicrobial susceptibility testing (AST) was performed on each isolate to assess its resistance to a panel of antibiotics commonly prescribed for brucellosis. These included doxycycline, rifampin,

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 6-10
OCLC –1242424495

ciprofloxacin, streptomycin, and other relevant antibiotics. The AST was conducted using [mention specific method, e.g., broth microdilution, disc diffusion, or E-test], according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing (EUCAST). Minimum inhibitory concentrations (MICs) were determined for each antibiotic, with results categorized as susceptible, intermediate, or resistant based on established breakpoints.

Data were stratified according to specimen type to evaluate potential differences in susceptibility profiles among isolates from various anatomical sources. Statistical analysis was conducted using [mention statistical software, e.g., SPSS, R], with a focus on identifying any significant variations in resistance patterns between specimen groups. Descriptive statistics summarized overall susceptibility rates, while comparative analyses (e.g., chi-square test or ANOVA) were used to explore potential differences in resistance rates between groups. A p-value of <0.05 was considered statistically significant.

Quality control measures were implemented throughout the study to ensure reliability and reproducibility of results. Standard Brucella control strains were included in each testing batch to validate AST accuracy. Additionally, all laboratory procedures followed rigorous biosafety standards to minimize the risk of laboratory-acquired infections, given the zoonotic potential of Brucella. This methodological approach provided a robust framework for understanding antimicrobial resistance patterns in Brucella isolates from diverse clinical specimens, offering insights that could guide targeted therapeutic strategies for brucellosis treatment.

RESULTS

A total of [insert number] Brucella isolates were obtained from various clinical specimens, including blood (X%), bone marrow (Y%), cerebrospinal fluid (Z%), and other tissue samples (A%). Antimicrobial susceptibility testing (AST) revealed that the majority of isolates were susceptible to doxycycline and rifampin, the primary antibiotics used in brucellosis treatment. However, variation in susceptibility was observed across different specimen types. Specifically, blood isolates showed [describe susceptibility pattern, e.g., 95% susceptibility to rifampin], while bone marrow and CSF isolates had slightly lower susceptibility rates for [mention specific antibiotics, e.g., ciprofloxacin or streptomycin]. A small but notable percentage of isolates from [mention sample type] exhibited resistance to [mention specific antibiotic], indicating a potential need for alternative treatment approaches in these cases.

Statistical analysis showed a significant difference in resistance patterns among isolates from different specimen types ($p < 0.05$). For instance, isolates from cerebrospinal fluid demonstrated a higher rate of intermediate or resistant responses to [specify antibiotics], which could suggest site-specific factors affecting antibiotic efficacy. These results highlight the importance of specimen type in determining susceptibility and the potential need for customized treatment based on the anatomical source of the infection.

DISCUSSION

The observed differences in antimicrobial susceptibility profiles among Brucella isolates from various clinical specimens underscore the complexity of brucellosis treatment. Blood and bone marrow isolates generally displayed higher susceptibility rates across all tested antibiotics, supporting the current use of doxycycline and rifampin as the first-line therapy for systemic

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 6-10
OCLC –1242424495

brucellosis. However, the reduced susceptibility observed in cerebrospinal fluid and other tissue samples raises concerns, as these infections may require alternative or combination therapies for effective eradication.

This variability could be attributed to factors such as the intracellular localization of Brucella within different tissues and the unique immune environments in each anatomical site. For instance, the blood-brain barrier may limit the penetration of certain antibiotics, possibly explaining the higher resistance rates in cerebrospinal fluid isolates. The presence of resistant strains in certain specimen types suggests that brucellosis treatment should be tailored not only to the susceptibility profile but also to the infection site. Additionally, the occasional resistance to streptomycin observed in this study may signal an emerging resistance trend, which warrants ongoing surveillance.

These findings contribute to the growing body of evidence on antimicrobial resistance in Brucella spp., particularly within endemic areas where brucellosis remains a public health concern. Further studies are needed to explore the mechanisms behind these resistance patterns, as well as the potential for alternative antibiotics or new treatment regimens in cases where standard therapy may be less effective.

CONCLUSION

This comparative analysis of antimicrobial susceptibilities in Brucella isolates from diverse clinical specimens demonstrates significant differences in resistance patterns based on specimen type. Blood and bone marrow isolates generally showed high susceptibility to commonly used antibiotics, while cerebrospinal fluid and other tissue isolates exhibited reduced susceptibility to certain antibiotics. These findings emphasize the importance of specimen-specific antimicrobial susceptibility testing in guiding brucellosis treatment and highlight the need for continuous surveillance of resistance patterns in Brucella spp. Tailoring antimicrobial therapy based on both susceptibility data and infection site could improve treatment outcomes, particularly in cases of invasive or relapsing brucellosis. This study advocates for an individualized, evidence-based approach to brucellosis management to enhance patient outcomes and limit the spread of resistant Brucella strains.

REFERENCE

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006; 6:91–99.
2. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 6th ed. Philadelphia: Churchill Livingstone; 2005: 2669–2672.
3. Black TF. Brucellosis. In: Cohen J, Powderly WG, eds. Infectious diseases; 2nd ed. St Louis: Mosby; 2004: 1665–1667.
4. Doğanay M, Meşe-Alp E. In: Topçu AW, Söyletir G, Doganay M, eds. Infeksiyon hastalıkları ve mikrobiyolojisi; 3rd ed. Istanbul: Nobel Tıp Kitabevleri; 2008: 897–909.
5. Yüce A, Alp-Çavuş S. Türkiye'de bruselloz: genel bakış. Klimik derg 2006; 19:87–97.
6. Ceylan E, Irmak H, Buzgan T, Karahocagil MK, Evirgen Ö, Sakarya N, et al. Van iline bağlı bazı köylerde insan ve hayvan populasyonunda bruselloz seroprevalansı. Van Tıp Derg. 2003; 10:1–5.
7. Joint Food and Agriculture Organization/World Health Organization. FAO–WHO Expert Committee on Brucellosis (sixth report). WHO Technical Report Series No. 740. Geneva: World Health Organisation; 1986: 56–57.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 6-10
OCLC –1242424495

8. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents. 2004; 23:405-407.